Targeting ER-Golgi Homeostasis in an Advantageous Therapeutic Strategy in Lung Cancer
Phase 0
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
The Combined Effect of Hsp90 Inhibitor and HDAC/Proteasome Inhibitors on Lung Cancer Cell Fate and ER-Golgi Homeostasis Will be Examined.
Both
The Combined Effect of Hsp90 Inhibitor and HDAC/Proteasome Inhibitors on Lung Cancer Cell Fate and ER-Golgi Homeostasis Will be Examined.
Trial Information
Targeting ER-Golgi Homeostasis in an Advantageous Therapeutic Strategy in Lung Cancer
Inclusion Criteria:
- PATIENTS WITH PROVED DIAGNOSIS OF LUNG CARCINOMA THAT ARE CANDIDATS FOR RADICAL
SURGICAL TREATMENT
Exclusion Criteria:
- PATIENTS WITH SUSPICION FOR LUNG CARCINOMA WITHOUT PATHOLOGYCAL DIAFNOSIS BEFORE
SURGERY
Type of Study:
Observational
Study Design:
Observational Model: Case Control, Time Perspective: Prospective
Authority:
israel: CLALIT HEALTH SERVICE
Study ID:
MMC10160-2010CTIL
NCT ID:
NCT01270399
Start Date:
January 2011
Completion Date:
January 2013
Related Keywords:
- The Combined Effect of Hsp90 Inhibitor and HDAC/Proteasome Inhibitors on Lung Cancer Cell Fate and ER-Golgi Homeostasis Will be Examined.
- Lung Neoplasms
Name | Location |
|---|
